Prospectus
Filed with ASX · · 58 pages · English
Summary by 6ix AI
Imugene Ltd has filed a prospectus for a capital raising initiative, which includes a placement and a share purchase plan to raise funds from investors. The prospectus outlines the offer of new shares, options, and convertible notes, detailing the terms and conditions for participation. It emphasizes the importance of reading the document in its entirety and consulting professional advisors before investing. The company aims to raise significant funds to support its operations and growth strategies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/prospectus-25
Story so far
Earlier from Imugene
- $20M placement and SPP, convertible notes amended
- 100% and 80% ORRs in Subset Indications in azer-cel study
- Trading Halt
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Imugene
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Complete Response in Concurrent BTKi azer-cel Cohort
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene